Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Solvonis Therapeutics ( (GB:SVNS) ) is now available.
Solvonis Therapeutics has announced an update regarding its issued share capital, confirming a total of 6,806,403,493 Ordinary Shares with one voting right each. This adjustment, which corrects a previous share issuance figure, is significant for shareholders as it affects calculations related to their shareholding interests.
More about Solvonis Therapeutics
Solvonis Therapeutics plc is an emerging biopharmaceutical company focused on developing novel medicines for high-burden central nervous system disorders.
Average Trading Volume: 66,563,279
Technical Sentiment Signal: Buy
Current Market Cap: £21.7M
See more insights into SVNS stock on TipRanks’ Stock Analysis page.